Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "Road"

1283 News Found

Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules
News | January 19, 2022

Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules

The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space


Dr Charles Woler is the new Chairman of Sygnature Discovery
People | January 17, 2022

Dr Charles Woler is the new Chairman of Sygnature Discovery

Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021


AIIMS now uses ImmersiveTouch for surgeries
Digitisation | January 14, 2022

AIIMS now uses ImmersiveTouch for surgeries

Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training


AstraZeneca and Scorpian Therapeutics partner to target novel cancer treatments
Biotech | January 14, 2022

AstraZeneca and Scorpian Therapeutics partner to target novel cancer treatments

The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival


Amgen and Arrakis collaborate for small molecule therapeutics
Biotech | January 12, 2022

Amgen and Arrakis collaborate for small molecule therapeutics

Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen


Covaxin booster neutralises Omicron and Delta variants: Study
News | January 12, 2022

Covaxin booster neutralises Omicron and Delta variants: Study

The study will be published on the pre-print server, medRXiv, shortly


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Pfizer and Beam enter research collaboration for In Vivo base editing programme
Biotech | January 11, 2022

Pfizer and Beam enter research collaboration for In Vivo base editing programme

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma